Suggestions
Manuel Sanchez-Felix
VP Drug Delivery Search & Evaluation
Manuel Sanchez-Felix is a distinguished scientific leader with a robust background in discovery and development spanning over two decades within the pharmaceutical industry.
His expertise lies in various areas such as Novel Drug Technologies evaluations, project management, leading cross-functional teams, and defining strategic objectives.
Manuel has garnered hands-on experience across different facets of the Pharmaceutical industry including discovery, development, and manufacturing, with a profound understanding of sectors like oncology, CNS, cardiovascular, and musculoskeletal fields.
He is highly skilled in the development and application of high throughput screening methods, computational tools for drug molecule assessment, management of external alliances, and due diligence processes.
Manuel possesses deep knowledge in PK/PD and utilizes tools like GastroPlus modeling effectively.
His proficiency extends to the development and selection of novel formulations like Liposomes, dendrimers, and various delivery methods.
Manuel has demonstrated excellence in verbal and written communication skills, essential for effective collaboration and leadership.
Manuel Sanchez-Felix pursued his Ph.D. in Chemistry at the University of Surrey and completed his early education at St Peters and Merrow Grange School in Guildford, Surrey, UK.
Throughout his career, Manuel has held key positions in distinguished organizations such as Halozyme, Inc., Middlesex Community College Biotechnology Program, Purdue University, Novartis Institutes for BioMedical Research (NIBR), Paraytec Ltd, and Eli Lilly & Company.
He also co-founded Sciona, Inc., where he served as the Chief Technical Officer, showcasing his entrepreneurial spirit alongside his scientific expertise.
Highlights
Proud to be part of a cross function industry group who published on the "Pharmaceutical and biotech industry perspective on opitmizing paitent experience and treatment adherence through subcutaneous drug delivery design." It provides the output from a industry survey of parameters impacting patient experience.
Article is in Advanced Drug Delivery Reviews, vol. 209, June 2024, https://lnkd.in/enDTVSsh
David Kang is #hiring. Know anyone who might be interested?
